<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627701</url>
  </required_header>
  <id_info>
    <org_study_id>PA-CP-20</org_study_id>
    <nct_id>NCT04627701</nct_id>
  </id_info>
  <brief_title>CLEAR Study: Evaluation of the Safety and Efficacy of the ClearRing System for the Treatment of BPH</brief_title>
  <official_title>Evaluation of the Safety and Efficacy of the ClearRing System for the Treatment of Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProArc Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProArc Medical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ProArc Medical ClearRing system is a prostatic reshaping device that is designed to treat&#xD;
      Lower Urinary Tract Symptoms (LUTS) due to BPH. During the procedure an implant is delivered&#xD;
      into the prostate tissue obstructing the urethra and restricting urine flow. The delivery&#xD;
      system uses an electrocutting blade to perform a circular incision, in which the implant is&#xD;
      placed. The implant expands the obstructed area, and allows fluid flow through the prostatic&#xD;
      urethra&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in urinary related symptoms as evidenced by IPSS score</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>ClearRing Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ClearRing</intervention_name>
    <description>ClearRing Implantation</description>
    <arm_group_label>ClearRing Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male ≥45 years of age and ≤ 75 years old&#xD;
&#xD;
          2. Diagnosed with symptomatic benign prostatic hyperplasia (BPH)&#xD;
&#xD;
          3. International Prostate Symptom Score (IPSS) &gt;13&#xD;
&#xD;
          4. Participant understands and is willing to sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant comorbidities which would affect study participation.&#xD;
&#xD;
          2. Diagnosed or suspected prostate cancer.&#xD;
&#xD;
          3. Active Urinary Tract Infection (UTI)&#xD;
&#xD;
          4. Concomitant bladder or kidney stones&#xD;
&#xD;
          5. Confirmed or suspected malignancy of bladder&#xD;
&#xD;
          6. History or presence of strictures in the anterior urethra or bladder neck contracture&#xD;
             or detrusor muscle spasms&#xD;
&#xD;
          7. Bacterial prostatitis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 8, 2020</study_first_submitted>
  <study_first_submitted_qc>November 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>September 19, 2021</last_update_submitted>
  <last_update_submitted_qc>September 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

